title: Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
abstract: OBJECTIVE
  This trial investigated the safety and efficacy of paclitaxel and topotecan combination chemotherapy for patients with advanced cervical cancer (ACC).
  
  
  METHODS
  Patients with recurrent, persistent, or metastatic ACC and an ECOG performance status < or =2 were treated with 175 mg/m(2) paclitaxel on Day 1 and 1 mg/m(2) topotecan on Days 1-5 of a 21-day cycle with G-CSF support and the standard pretreatment regimen for paclitaxel. Patients were treated until disease progression or unacceptable toxicity.
  
  
  RESULTS
  Fifteen patients were enrolled, and 86 cycles of therapy (median, 5; range, 1-14) were administered. Grade 3/4 toxicities included anemia (47%), leukopenia (27%), neurotoxicity (13%), thrombocytopenia (13%), and diarrhea (13%). Among 13 evaluable patients, 7 (54%) responded (1 complete and 6 partial; 95% confidence interval = 29.2%, 76.8%). Three (23%) patients experienced stable disease. Progression-free and overall survival were 3.77 and 8.62 months, respectively.
  
  
  CONCLUSIONS
  The combination of paclitaxel/topotecan was generally well tolerated and active in the relapsed, recurrent, or metastatic ACC setting, with response rates comparable with those of other current ACC systemic therapies.
authors.affiliation: Department of Medicine, Columbia Presbyterian Medical Center, New York, NY 10032, USA. tiersten@canceercenter.columbia.esu
authors.forename: Amy D
authors.initials: AD
authors.lastname: Tiersten
authors.forename: Meredith J
authors.initials: MJ
authors.lastname: Selleck
authors.forename: Dawn L
authors.initials: DL
authors.lastname: Hershman
authors.forename: D
authors.initials: D
authors.lastname: Smith
authors.forename: Edward E
authors.initials: EE
authors.lastname: Resnik
authors.forename: Andrea B
authors.initials: AB
authors.lastname: Troxel
authors.forename: Lois B
authors.initials: LB
authors.lastname: Brafman
authors.forename: Laureen
authors.initials: L
authors.lastname: Shriberg
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D019772:Topotecan; D017239:Paclitaxel